Novo breathes life into Alzheimer's speculations after executive hunt
As the market awaits clarification on whether Novo Nordisk will move into the market for Alzheimer's treatments, the pharmaceutical firm embarks on a hunt for an executive position with this disease as one of its focus areas.
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN
Novo Nordisk now breathes life into the question of whether the Danish pharmaceutical firm is serious about officially starting the hunt for the gigantic market for pharmaceutical drugs against the dreaded brain disease Alzheimer's.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk cuts 450 positions in the US
For subscribers
